Dr Luis Garcia-Gancedo, Director Sensor Technology
In this talk I will give an overview of our main considerations for choosing and deploying wearable technologies in clinical trials. As an example I will explain how we went about introducing a specific wearable in one of our ongoing studies, and the impact that this is expected to make in assessing the efficacy of the treatment investigated.
講演者の経歴 (Luis Garcia-Gancedo)
Dr Luis Garcia-Gancedo is the Director of Digital Biomarkers at GlaxoSmithKline (GSK). With a background in Physics and Electronic Engineering, Luis spent a number of years as a Research Associate in the Engineering Department at the University of Cambridge and as a College Lecturer at Newnham College (University of Cambridge) before joining GSK.
Currently he leads the development of a strategic portfolio of novel digital measures of disease progression (digital biomarkers) to support GSK's pipeline of innovative medicines. This includes pioneering new digital tools and data science approaches to investigate these measurements in our therapeutic clinical studies with the aim to collect 'real-world' data that reflects a reasonable approximation of how study participants usually live their lives, ultimately enabling a better understanding of disease manifestation and a better assessment of drug efficacy.
Luis' long-term mission is to use digital technologies to improve the lives of patients, helping them do more, feel better and live longer.
View GSK Timeline
GlaxoSmithKline (GSK) plc is one of the largest pharmaceutical companies in the world. With headquarters in Brentford, London, GSK has 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.